Trial Information
The Role of HER Receptor Family as Indicator of Prognosis and Drug Responsiveness in Locally Advanced Prostate Cancer
Inclusion Criteria:
- Patients were eligible if they had histologically confirmed adenocarcinoma of the
prostate and the following high-risk features: (1) clinical stage T3a disease with
(2) Gleason sum of 7 with a predominant component of 4 (i.e., Gleason 4 + 3 = 7) or
(4) Gleason sum of 8, 9 or 10.
Exclusion Criteria:
- Prior hormonal therapy,
- Prior radiation,
- Prior investigational agents,
- Prior malignancy within the last five years or had any other serious medical or
psychiatric condition or illness that would not permit the patient to be managed
according to the protocol were excluded.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment
Outcome Measure:
PSA recurrence rate stratified according to treatment modalities
Principal Investigator
Giovanni Luca Gravina, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of L'Aquila
Authority:
Italy: Ethics Committee
Study ID:
BCLT-1236
NCT ID:
NCT00418080
Start Date:
April 2002
Completion Date:
December 2006
Related Keywords:
- Prostate Cancer
- Prostatic Neoplasms